Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 3/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.35 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ADK | P55263 | 2/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | FES | P07332 | 1/20 | 0.33 |
| ▸ | ROS1 | P08922 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3917466 | 0.75 | HTT (0.41) | HRH3ENPP1CDK1CCNB2CCNB1 | |
| SCHEMBL14780097 | 0.73 | CDK2 (0.52) | CDK1CCNB2CCNB1CCNB3ADORA2A | |
| SCHEMBL14779312 | 0.71 | CSF1R (0.53) | CDK1CCNB2CCNB1CCNB3ADORA2A | |
| SCHEMBL22524347 | 0.71 | CCNB2 (0.46) | CDK1CCNB2CCNB1CCNB3FLT1 | |
| SCHEMBL5265519 | 0.70 | ADORA2A (0.36) | ADORA2AADORA1SMN1; SMN2 | |
| SCHEMBL3918824 | 0.70 | ENPP1 (0.42) | HRH3ENPP1CDK1CCNB2CCNB1 | |
| SCHEMBL22524348 | 0.70 | CCNB2 (0.45) | CDK1CCNB2CCNB1CCNB3CYP1A2 | |
| SCHEMBL14779454 | 0.68 | SMN1; SMN2 (0.55) | CDK1CCNB2CCNB1CCNB3CYP1A2 | |
| SCHEMBL22524353 | 0.67 | CCNB2 (0.42) | CDK1CCNB2CCNB1CCNB3FLT1 | |
| SCHEMBL22524323 | 0.66 | CCNB2 (0.41) | CDK1CCNB2CCNB1CCNB3FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-2016077-A2 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007125315-A2 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125315-A2 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| EP-1812003-A1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006046023-A1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253718-A1 | Pharmaceutical Compounds | GRK3, CNKSR1, CSNK1G3 | HRH3 449/4885ENPP1 4517/4885CDK1 47/4885 |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | OXSR1, CDK1, CDK3 | HRH3 228/4885ENPP1 2813/4885CDK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.